Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04349280 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04349280 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 25 participants.
The verdict
NCT04349280, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy.
Interventions
- DRUG Bintrafusp alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04349280
The ClinicalTrials.gov registry entry for NCT04349280 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bintrafusp alfa is the first listed.
NCT04349280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04349280 about?
NCT04349280 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer". The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy.
What is the current status of trial NCT04349280?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-10-15. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT04349280?
The interventions under investigation include: Bintrafusp alfa (DRUG).
Who is sponsoring clinical trial NCT04349280?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.